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Abstract
The budding yeast Saccharomyces cerevisiae is a useful eukaryote model organism for 
application to chemical biology studies, for example, drug screening, drug evaluation, 
and target identification. To use yeast for chemical biology research, however, it has been 
necessary to construct yeast strains suitable for various compounds because of their high 
drug resistance. Hence, the deletion of all multidrug resistance genes except for those 
that are important for viability and for genetic experiments/manipulation could increase 
the drug sensitivity without influencing the transformation, mating, or sporulation effi-
ciency. There are two major factors conferring multidrug resistance in S. cerevisiae: one is 
the drug efflux system and the other is the permeability barrier. We therefore constructed 
a strain which shows high sensitivity to multiple drugs by disrupting the drug efflux 
system using ATP-binding cassette transporters and suppressing the membrane barrier 
system by introducing an ERG6-inducible system. In this review, we discuss the construc-
tion of our multidrug-sensitive yeast strains and their application in chemical biology.
Keywords: multidrug-sensitive yeast, drug efflux system, permeability barrier system, 
drug target identification, drug screening
1. Introduction
1.1. Screening and target identification of bioactive small molecules: important  
processes in chemical genetics
The screening of bioactive small molecule compounds is the most important process in drug 
development. Natural products which have structural diversity isolated from microorganisms, 
© 2018 The Author(s). Licensee InTech. This chapter is distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is properly cited.
plants, and animals are useful sources in the field of drug development [1]. Structurally, new 
natural products might show novel activities such as antimicrobial, antiviral, and antitumor 
activities. These natural products also provide useful information for medicinal chemistry, and 
allow the development of new synthetic compounds as novel medicines. For example, eribulin, 
a semi-synthetic derivative of halichondrin B, has been approved as an anti-cancer drug [2–4]. 
Therefore, the screening and identification of new small molecules open new avenues for drug 
development. There are two major ways to identify bioactive small molecules: phenotypic 
screening and target-based screening. Phenotypic screening is based on cytotoxicity [5–7], cell 
cycle arrest [8], immune-suppression [9], and morphological changes [10] of drug-treated cells, 
fungi, and bacteria. Target-based screening is performed based on measurable readouts such 
as enzymatic activity inhibition [11] or drug-protein interaction [12]. These approaches have 
identified useful small molecules and medicines.
Target identification (Target ID) of small molecules is also quite important in order to develop 
safe and useful drugs [13]. Thalidomide, a cautionary example, was used as a sedative a half-
century ago before it was found to be teratogenic and to cause multiple birth defects [14]. 
However, thalidomide is also used in the treatment of Hansen’s disease, myeloma [14], and 
so on. In addition, immunomodulatory drugs derived from thalidomide have been developed 
as a new class of anti-cancer drugs and novel medicines for treating ribosomopathies such as 
5q-syndrome [15]. Recently, cereblon, a substrate receptor of the CRL4 E3 ubiquitin ligase, 
has been identified as a primary target of thalidomide teratogenic [16] and anti-cancer [15] 
activity. These lines of research provide useful information that cereblon may pose a risk of 
teratogenic activity and simultaneously serve as an attractive molecular target for immuno-
modulatory drug development. To identify the relevant target molecules and target path-
ways, indirect and direct approaches have been used [13]. The indirect approaches include 
phenotypic analysis and large-scale analysis such as proteomic and genome-wide analyses. 
Some specific changes in cell morphology, cell cycle arrest, and other phenotypes provide us 
useful information for predicting targets of the drugs. Based on this property, Morphobase, 
an encyclopedic database of the morphological changes that occur in drug-treated cells, has 
been constructed and applied to drug target discovery [17]. Large-scale analyses such as pro-
teomics, metabolomics, and transcriptome analysis of drug-treated cells have been performed 
to predict the target pathways of bioactive small molecules [18]. Genome-wide genetic studies 
are also frequently used for drug target ID. For example, synthetic lethal/sick genetic interac-
tion analyses [19, 20], genome-wide overexpression screening [21], and haploinsufficiency-
chemical sensitive assays [22] have been used to analyze the mode of action of various drugs. 
On the other hand, direct approaches, such as affinity probe approaches and genetic analy-
ses, are quite useful to identify the direct target molecules of drugs. By using affinity probe 
approaches, the targets of thalidomide [16] and FK506 [23] have been identified. Genetic 
analysis is another powerful method of identifying not only drug targets [24–29] but also the 
signaling pathway affected by a drug. Genetic studies using model organisms such as yeast 
have contributed to identification of the target molecules of bioactive compounds.
The identification of new bioactive small molecules and elucidation of their target mol-
ecules/signaling pathways are important not only for developing medicines but also for 
basic science. Such compounds are a useful tool for understanding the fundamental protein 
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functions in cells. Well-known examples are famous immunosuppressants such as FK506, 
cyclosporine, and rapamycin. These compounds inhibit immunophilin and T-cell activa-
tion through different mechanisms [30]. Studies of these compounds have revealed their 
detailed immunoreaction mechanisms [30]. Mitotic inhibitors are another example. Mitotic 
spindle formation and chromosome segregation are fast processes that are completed within 
approximately 1 hour. Therefore, by taking advantage of rapid pharmacological interven-
tion, studies using microtubule inhibitors (αβ-tubulin inhibitors [31–33] or γ-tubulin inhibi-
tor [12]), mitotic kinesins (Eg5 [34, 35]), and mitotic kinase inhibitors (aurora kinases [36, 
37], Cdk1 [38], Plk1 [39, 40], Mps1 [41, 42]) highlighted useful information regarding the 
temporal regulation of mitotic spindle architecture and faithful chromosome segregation. 
These findings could in turn contribute to further drug development. Therefore, target ID of 
newly found useful bioactive compounds is quite an important process in both basic science 
and medicine development.
1.2. Saccharomyces cerevisiae, a useful model organism for chemical genetics
Saccharomyces cerevisiae is one of the most frequently used model organisms in chemical 
genetics. The properties of S. cerevisiae along with easy-to-use genetic analyses, mutational 
analyses, gene disruption, and genome modification have facilitated both chemical screen-
ing and target ID (Table 1). For example, the target of rapamycin (TOR) has been found by 
genetics using S. cerevisiae [29]. In addition, S. cerevisiae is useful for chemical screening [43, 
44]. However, S. cerevisiae generally shows higher resistance against various compounds 
compared with mammalian cells, except in the case of a few compounds such as rapamy-
cin (Table 2). This disadvantage limits the application of S. cerevisiae in chemical screening. 
Therefore, S. cerevisiae showing sensitivities against drug of interest has been quite useful. 
For example, S. cerevisiae quadruple deletion mutant lacking yrr1, yrs1, pdr1, and pdr3 was 
constructed for the analyses of target molecule of reveromycin A. However, construction of 
sensitive yeast suitable for each compound is a time-consuming process. To overcome this 
drawback, we developed two multidrug-sensitive strains which have proven quite useful for 
Compound Approach Finding Ref.
Benomyl Pathway 
analysis
Identification of Mad1, Mad2, Mad3 as mitotic spindle checkpoint 
proteins by using benomyl sensitive mutants
[31]
Benomyl Pathway 
analysis
Identification of Bub1, Bub2, Bub3 as mitotic spindle checkpoint 
proteins by using benomyl sensitive mutants
[32]
Reveromycin A Target ID Identification of ILS1 as a target of reveromycin A [27]
Curvularol Target ID Identification of RPL3 as a target of curvularol [28]
Rapamycin Target ID Identification of TOR as a target of rapamycin [29]
Eudistomin C Target ID Identification of RPS14 as a target of eudistomin C [50]
Splitomicin Screening Identification of splitomicin as a NAD+-dependent histone 
deacetylase inhibitor
[51]
Table 1. The examples of chemical genetics studies using S. cerevisiae.
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research in chemical biology. There are two major systems conferring multidrug resistance 
in S. cerevisiae: one is the drug efflux system, which exports drugs into vacuoles or outside of 
cells, and the other is the permeability barrier, which blocks the penetration of drugs into the 
cells (Figure 1). The drug efflux system consists of ATP-binding cassette (ABC) transporters 
that export xenotoxic compounds outside of cells or inside of vacuoles, and their transcrip-
tional factors [45–47]. S. cerevisiae has at least 16 ABC transporters, of which Pdr5p, Snq2p, and 
Yor1p confer multidrug resistance by exporting bioactive small molecules out of cells. Four 
transcriptional factors (Pdr1p, Pdr3p, Pdr8p, and Yrr1p) up-regulate the transcription of most 
of the ABC transporters [45–47]. A permeability barrier is conferred by ergosterol in the yeast 
plasma membrane. Therefore, ABC transporter-related genes and ergosterol synthesis genes 
were frequently disrupted to construct drug-sensitive strains. For instance, a strain in which 
pdr1, pdr3 (genes encoding transcriptional factors for ABC transporters), and erg6 (a gene 
involved in ergosterol synthesis) were disrupted was used for drug screening [43]. However, 
the erg6 deletion mutant shows decreased transformation and sporulation efficiencies that 
are essential for yeast genetic analysis. In addition, some of the transporters located in the 
vacuole membrane are involved in the detoxination of metabolites as well as xenotoxins, and 
their disruption results in growth defects. Therefore, to make a yeast strain sensitive to a wide 
range of drugs, it is necessary to suppress both efflux and barrier systems without affecting 
the genetic properties and growth rate. Hence, we speculated that the disruption of all ABC 
transporters located on the plasma membrane that are not important for viability and genetic 
experiments or for the conditional expression regulation of the ERG6 gene could increase the 
drug sensitivity without influencing the transformation, mating, or sporulation efficiency.
In this review, we discuss the construction of two multidrug-sensitive yeast strains, 
12geneΔHSR [48] and 12geneΔHSR-iERG [49], which are available for genetic analysis. We 
also discuss the application of these strains in drug screening and target ID [50].
Mammalian cell line (HeLa) Budding yeast (BY4741)
Cycloheximide (μM) 0.2 270
Digitonin (μM) 0.4 1.9
Fluphenazine (μM) 13 51
Latrunculin A (nM) 0.2 >240
4-Nitroquinoline 1-oxide (μM) 0.1 7.1
Rapamycin (nM) >300 7.1
Staurosporine (μM) 0.1 15.1
Tunicamycin (μM) 1.8 >120
HeLa cells (3 × 103 cells/well in 96 well plate) and BY4741 cells (3.8 × 105 cells/well in 96 well plate) were treated with 
various concentrations of compounds for 48 and 8 h, respectively. Cell viabilities were determined by WST-8 (Dojindo, 
Kumamoto, Japan) and IC50 values were calculated.
Table 2. The IC50 values of compounds against HeLa cells and S. cerevisiae.
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Figure 1. The work flow of the construction of multidrug-sensitive strains. (A) The parental strain, BY4741, possesses 
high genetic manipulation availability, but shows high drug resistance. (B) 12geneΔ0HSR, created by disruption of the 
drug efflux system and introduction of the RME1(ins-308A) mutation, achieves drug-sensitivity without compromising 
the genetic manipulation availability. (C) 12geneΔ0HSR-iERG was created by the insertion of a gal1 promoter into ERG6. 
This strain shows high drug sensitivity but drastically decreased genetic manipulation availability under the glucose 
condition, because ERG6p expression is repressed. Instead, genetic manipulation is available under the galactose 
condition through enhancement of the ERG6p expression.
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2. Construction and application of multidrug-sensitive yeast strains
2.1. Construction of multidrug-sensitive yeast strains
We constructed a multidrug-sensitive yeast strain by disrupting 12 ABC transporter-related 
genes and suppressing the ERG6 gene. The work flow is shown in Figure 1. As a first step, 
we focused on drug efflux systems. The drug efflux system composed of ABC transporters 
confers resistance against a wide variety of compounds [45–47]. Therefore, it is difficult 
to predict which transporters will confer drug resistance against the drug of interest. We 
thus decided to construct the 12geneΔ0 strain through the disruption of all of the ABC 
transporters involved in drug export located on the plasma membrane and transcription 
factors involved in multidrug resistance specifically on a BY4741 background [48]. Gene 
disruption of eight gene-encoding ABC transporters (AUS1, PDR5, PDR10, PDR11, PDR12, 
PDR15, SNQ2, and YOR1) and four genes encoding transcriptional factors (PDR1, PDR3, 
PDR8, and YRR1) was carried out using a PCR-based markerless gene disruption method 
modified from the delitto perfetto method [52]. Because 12geneΔ0 leaves no marker genes 
in the genome, auxotroph markers which the parental strain originally possesses can be 
used for further studies. To use 12geneΔ0 for chemical genetics, it is important to show not 
only its multidrug sensitivity but also its transformation, mating, and sporulation efficien-
cies, which are necessary for genetic analysis. The transformation and mating efficiency of 
12geneΔ0 were on the same order as those of the parental strain BY4741 (Table 3). However, 
the sporulation efficiency was drastically decreased in 12geneΔ0 (Table 3). It was reported 
that single-nucleotide polymorphisms of three genes (a noncoding regulatory region of 
RME1(ins-308A), and two missense mutations in TAO3 and MKT1) are involved in sporula-
tion efficiency, and when these mutations were introduced in S288c, the parental strain of 
BY4741, the sporulation efficiency increased [53]. We therefore introduced the RME1(ins-
308A) and MKT1(D30G) mutations into 12geneΔ0. Although both mutations increased 
the sporulation efficiencies, the MKT1(D30G) mutant formed petite colonies as reported 
previously [54]. Therefore, we decided to use the RME1 mutant for our studies, and the 
strain created was named 12geneΔ0HSR (12geneΔ0 strain showing High Sporulation by 
RME1(ins-308A) mutation) [48]. 12geneΔ0HSR showed sporulation efficiency comparable 
to that of BY4741. By testing the drug sensitivities of the 12geneΔ0HSR, BY4741Δerg3, and 
BY4741Δerg6 strains, we revealed that there are different spectrums of drug resistance con-
ferred by the efflux and barrier systems (Figure 2) [48], suggesting that it is necessary to 
disrupt both the drug efflux and permeability barrier systems to make a strain with high 
sensitivity against a wide range of multiple drugs. To disrupt the permeability barrier sys-
tem without affecting any of the genetic properties, we introduced the conditional expres-
sion promoter GAL1p in the ERG6 gene in 12geneΔ0HSR (Figure 1) [49]. The constructed 
strain, 12geneΔ0HSR-iERG6, showed improved sensitivities to several compounds under 
the glucose condition (ERG6 suppression), and it exhibited sufficient transformation and 
sporulation efficiencies under the galactose condition (ERG6 expression) (Table 3). Because 
of its high sensitivities to several compounds, the 12geneΔ0HSR-iERG6 strain will be a use-
ful tool in chemical biology studies.
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2.2. Application 1: drug screening
2.2.1. Availability of 12geneΔ0HSR-iERG6 in drug screening
In general, S. cerevisiae exhibits high levels of drug resistance, which is an obstacle for drug 
screening. In fact, most of the compounds used for clinical or basic research show higher 
IC
50
 values against S. cerevisiae than against mammalian cells (Table 2). Therefore, multi-
drug-sensitive strains of S. cerevisiae—for example, the pdr1 pdr3 erg6 triple mutant or pdr1 
pdr3 yrs1 yrr1 quadruplex mutant—have been used for drug screening [43, 55]. To test 
the superiority of our strain, we screened mitochondrial inhibitors from microbial second-
ary metabolites and compared the hit ratio of 12geneΔ0HSR-iERG6 with that of BY25929 
(yrs1::HIS3 yrr1::TRP1 pdr1::hisG pdr3::hisG), a multidrug-sensitive quadruplex mutant 
(Tables 4 and 5).
Transformation efficiency 
(Cfu/μg)
Mating efficiency 
(%)
Sporulation efficiency 
(%)
BY4741 9.6 × 105 ± 2.2 × 105 17.7 ± 7.5 21.9 ± 6.8
Δerg6 55.0 ± 51.3 4.8 ± 1.7 9.4 ± 4.7
12geneΔ0 1.2 × 105 ± 2.0 × 104 15.7 ± 5.3 5.0 ± 2.9
12geneΔ0HSR N.D. N.D. 28.8 ± 4.6
12geneΔ0HSR-iERG6 (under glucose 
condition)
7.0 ± 8.2 6.4 ± 2.2 0.0 ± 0.0
12geneΔ0HSR-iERG6 (under galactose 
condition)
3.0 × 104 ± 2.4 × 104 N.D. 10.7 ± 3.0
Values are mean ± S.D. calculated from three independent experiments. These data are edited from Figure 1 of Ref. [48] 
for BY4741, Δerg6, 12geneΔ0, and 12geneΔ0HSR, or Figure 2 of Ref. [49] for 12geneΔ0HSR-iERG6.
Table 3. Comparison of the efficiencies of transformation, mating and sporulation between BY4741, erg6 disruptant and 
12geneΔ0HSR.
Figure 2. Drugs to which resistance was conferred by ABC transporters, ergosterol or both systems (indicated by 
underlining), respectively.
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To identify the mitochondrial inhibitors, we used the difference in cell growth between the 
glucose medium and the glycerol medium. Yeast can use glycerol as a respiratory substance 
after the conversion to dihydroxyacetone phosphate via glycerol-3-phosphate by cytosolic 
and mitochondrial enzymes, GUT1p and GUT2p, respectively. Therefore, yeast could grow 
even in the presence of a mitochondrial inhibitor in glucose medium because of anaerobic res-
piration, but not in glycerol medium in which one of the metabolites in glycolysis, dihydroxy-
acetone phosphate, could not be produced. Therefore, we compared the growth inhibition 
induced by microbial broth samples on glucose medium (1% yeast extract, 2% polypeptone, 
2% glucose, 1.5% agar) with that on glycerol medium (1% yeast extract, 2% polypeptone, 3% 
glycerol, 1.5% agar), and chose the broth which inhibited yeast growth on glycerol medium 
but not on glucose medium [55]. Growth inhibition activities of microbial broth samples were 
evaluated using the paper disc method on agar plates inoculated with recombinant S. cere-
visiae strains. In detail, 6 mm sterile filter discs impregnated with each compound solution 
(10 μl) were placed on the agar plate using a forceps (medium volume; 30 ml/plate, cell num-
ber; 1.5 × 106 cells/plate, plate dimension; 144 × 100 × 14.5 mm, square shape), and the plates 
were incubated at 30°C for 48 h. After incubation, the diameters of the zone of inhibition were 
measured with a vernier caliper. As shown in Table 4, the hit ratio using the quadruplex 
mutant, BY25929, was about 5%. Because the hit ratio when wild-type yeasts (W303-derived 
yeast strains) were used in a similar screening system was 1.4% (fungus samples 0.5% (44 total 
hits among 8610 samples), actinomycetes samples 3.2% (125 total hits among 3912 samples), 
this result suggests that the quadruplex mutant is useful for drug screening with a high hit 
ratio. Indeed, a novel compound, decatamariic acid, was isolated as a mitochondrial inhibi-
tor using the quadruplex mutant [55]. Moreover, the hit ratio using 12geneΔ0HSR-iERG6 
increased to about 8% (Table 5).
Number of broth Number of hit broth Hit ratio (%)
Origin
Fungus 3144 270 8.6
Actinomycetes 3067 253 8.2
Total 6211 523 8.4
Table 5. Hit ratio of screening of mitochondrial inhibitor using 12geneΔ0HSR-iERG6.
Number of broth Number of hit broth Hit ratio (%)
Origin
Fungus 2664 149 5.6
Actinomycetes 5617 289 5.1
Total 8281 438 5.3
Table 4. Hit ratio of screening of mitochondrial inhibitor using quadruplex mutant, BY25929.
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To determine whether it is possible to isolate the novel compounds or not, we selected the 
microbial broths which were detected using 12geneΔ0HSR-iERG6 but not using the quadru-
plex mutant. We found a total of 46 broths (fungus origin: 16 broths; actinomycetes origin: 
30 broths) which inhibited the growth of 12geneΔ0HSR-iERG6 specifically. Among these 
broths, we selected two fungus broths for further purification of active metabolites, and iso-
lated 4,6′-anhydrooxysporidinone (1, fusoxypyridone [56]), pestalotic acid A (2), and three 
novel compounds (manuscript in preparation) (Figure 3). 4,6′-Anhydrooxysporidinone has 
been isolated from Fusarium oxysporum in the course of the screening of anti-angiogenesis 
inhibitors [57], but showed weak cytotoxicity against mammalian cell cultures (IC
50
 > 100 μM) 
and anti-MRSA activity (MIC = 100 μg/ml) [58]. Pestalotic acid A has been isolated from a 
Pestalotiopsis sp. as an antimicrobial compound containing a furylidine tetronic acid core [59]. 
Because of the lack of biological activity other than antimicrobial activities, the observation of 
antifungal activity is a novel insight. These results strongly suggest that 12geneΔ0HSR-iERG6 
would be useful for drug screening.
2.2.2. Screening of readthrough compounds
Because the usefulness of our strains was confirmed, we next performed the preliminary 
screening of compounds that show readthrough activities. Readthrough compounds allow the 
translational machinery to skip nonsense mutations encoding premature termination codons 
(PTCs) and could become medicines for hereditary diseases caused by PTCs (Figure 4). To 
date, many small molecules have been developed as readthrough drug candidates. Several 
forms of aminoglycoside antibiotics, such as gentamicin (3), G418 (4), and its analogues, have 
been reported to show readthrough activities (Figure 5) [60]. Barton-Davis et al. revealed that 
the dystrophin expression in mdx mice, an animal model of duchenne muscular dystrophy 
(DMD) is increased after the administration of gentamicin (3) [61]. Novel aminoglycosides 
derived from gentamicin, which showed readthrough activity against four different nonsense 
DNA constructs underlying genetic diseases, were also recently reported [62]. However, 
long-term treatment with aminoglycosides showed serious side effects such as nephrotoxic-
ity [63] and ototoxicity [64]. As a non-aminoglycoside readthrough compound, ataluren (5), 
which is a 1,2,4-oxadiazole derivative developed from a chemical library, promotes dystro-
phin production in primary muscle cells from humans and mdx mice (Figure 5) [65]. It was 
also found that (+)-negamycin (6), which is a dipeptide-like antibiotic containing a hydrazide 
Figure 3. Structure of 4,6′-anhydrooxysporidinone (1) and pestalotic acid A (2).
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structure [66], has readthrough activity and restores dystrophin expression in the muscles of 
mdx mice (Figure 5) [67]. In our structure-activity relationship study of (+)-negamycin, we 
discovered several more potent derivatives, including Leucyl-3-epi-deoxynegamycin (TCP-
126, 7) and TCP-112 (8) (Figure 5) [68, 69]. However, the activities of these compounds are not 
sufficient for medicine, and the mechanism of action of the readthrough activity remains to 
be elucidated.
To discover novel readthrough compounds, we constructed yeast strains for the screening 
of readthrough compounds using 12geneΔ0HSR. ADE2 is an enzyme that is essential to 
producing adenine in live yeast systems, and its mutation induced the accumulation of 
red pigment in vacuoles [70]. One of the ade2 auxotroph markers, ade2–101, has a nonsense 
mutation (ochre) at 190 bp [71]. Therefore, we introduced PTCs at the same site as in the 
ADE2 gene and inserted the ADE2 loci of 12geneΔ0HSR by pop-in/pop-out. The resulting 
strains 12geneΔ0HSR ade2-E64X required adenine for growth and formed red colonies in 
adenine-limited medium (Figure 6A). In contrast, most of the colonies appeared white on 
Figure 4. Nonsense mutation as a premature termination codon (PTC) and readthrough compounds. (A) mRNAs 
containing no PTC are translated into full-length and functional proteins. (B) In the case of mRNAs containing PTC, 
translation stops at PTC and non-functional truncated proteins are synthesized. (C) In the presence of readthrough 
compounds, even mRNAs containing PTC are translated into full-length and functional proteins.
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medium containing TCP-126 (Figure 6B), suggesting that TCP-126 evoked readthrough in 
ade2-E64X. In addition, DMSO solution (3 μl) containing readthrough compounds (G418 
or negamycin analogues including TCP-126) induced the white halo on the 12geneΔ0HSR 
ade2-E64X strain-inoculated plate after 4 days incubation (Figure 6C). These results 
indicated that 12geneΔ0HSR ade2-E64X is suitable for use in the qualitative analysis of 
readthrough activity.
Next, we initiated a high-throughput screening of the readthrough compounds based on 
the halo assay using chemical library. This screening is underway, but already several hit 
compounds have been found, including rapamycin (9) [72], wortmannin (10) [72], and 
A23187 (11) [73] (Figure 7). These data provided further evidence of the usefulness of the 
12geneΔ0HSR ade2-E64X strains for identifying and elucidating the mechanism of action of 
readthrough drugs.
2.3. Application 2: target ID
Since our strains show multidrug sensitivity without a decrease in genetic availability, they 
should also be useful for performing target ID for drugs and the mechanism evaluation of 
compounds, especially those which are only available in limited amounts, such as natural 
products. Here we show an example of target ID [50]. Eudistomin C (EudiC, Figure 8), a natu-
ral product isolated from the Caribbean tunicate Eudistoma olivaceum [74, 75] shows broad-
spectrum antiviral activity [76]. Because of a unique structural feature, oxathiazepine ring 
attached to a tetrahydro-β-carboline, EudiC has attracted attention as a lead compound for 
antiviral medicines. However, several trials for its clinical development have failed due to 
the strong cytotoxicity of EudiC. To reveal the cause of the cytotoxicity of EudiC, it is impor-
tant to identify the target molecule responsible for the cytotoxicity of EudiC. By using the 
yeast genetic approach, we found that a mutation in the RPS14A gene confers EudiC-specific 
Figure 5. Structure of readthrough compounds. Gentamicin (3) and G418 (4) are aminoglycoside-type readthrough 
compounds. Aataluren (5), (+)-negamycin (6), and negamycin derivatives (Leucyl-3-epi-deoxynegamycin (TCP-126, 7), 
TCP-112 (8)) are non-aminoglycoside-type readthrough compounds.
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Figure 6. The color of 12geneΔ0HSR ade2-E64X strains turned from red to white in the presence of readthrough 
compounds. (A) 12geneΔ0HSR ade2-E64X strains were plated on YPD containing 0.0005% adenine for 4 days. The 
wild-type strain (12geneΔ0HSR) formed white colonies, but 12geneΔ0HSR ade2-E64X strains formed red colonies. 
(B) 12geneΔ0HSR ade2-E64X strains were plated on SC-ADE + 0.0045% adenine with or without luecyl-3-epi-deoxy-
negamycin (TCP-126) for 4 days. The colonies formed on medium containing TCP-126 were white, suggesting that TCP-
126 evoked readthrough activity in the 12geneΔ0HSR ade2-E64X (TGA) strain. (C) DMSO and G418 were spotted on 0.5% 
agar containing 12geneΔ0HSR ade2-E64X strains overlaid on YPD containing 0.0005% adenine. After 4 days incubation, 
the halo that formed around the G418 was white.
The Yeast Role in Medical Applications40
resistance [50]. The work flow is shown in Figure 9. We used dTC033, one of the multidrug-
sensitive yeast strains which lacks 12 genes of the drug-efflux system. The sensitivity of 
dTC033 against EudiC was 25-fold higher than that of the parental strain BY4741. We isolated 
the 59 spontaneous mutants that show EudiC resistance. We then crossed these 59 EudiC-
resistant strains with OTA014, which has the same genotype as dTC033 (except for the mating 
type and RME1(ins-308A) mutation), and confirmed that 34 of the strains showed dominant 
resistance. Dominant resistance is predicted to be the mutation in target molecules which 
inhibits drug-target interaction rather than a lack of cell death signals activated by EudiC 
treatment (Figure 9). These 34 strains were further tested for their EudiC resistance under a 
higher concentration of EudiC, and 11 strains were selected as strongly resistant mutants. To 
confirm that the EudiC-resistant mutations of these mutants were not related to multi-drug-
resistance mechanisms such as drug efflux pump up-regulation, we checked the sensitivity 
Figure 7. Compounds showing readthrough activities in our screening. Rapamycin (9), wortmannin (10), and A23187 (11) 
were found as readthrough compounds in our assay system. The structures and haloes of these compounds are shown.
Figure 8. Chemical structure of eudistomin C (EudiC).
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of these mutants against several compounds. These strains did not show cross-resistance 
against 4-nitroquinoline 1-oxide, digitonin, cycloheximide, or rhodamine 6G, suggesting that 
these mutants obtained specific resistance against EudiC. We speculate that our strain cannot 
obtain cross-resistance easily due to its lacking all ABC transporters on the plasma mem-
brane. To select mutants which have a single mutation responsible for EudiC resistance, we 
performed a tetrad analysis of the spores derived from the diploid of the 11 selected mutants 
and confirmed that 8 of the strains showed a 2:2 segregation pattern for EudiC resistance. 
These eight strains were classified into three complementation groups, which we named 
YER1 (1 strain), YER2 (2 strains), and YER3 (5 strains). “YER” stands for Yeast Eudistomin 
C Resistance. Whole-genome sequence analysis of the YER strains and further confirmatory 
analyses, including the disruption of mutated genes in YER strains and the re-introduction of 
identified mutations into wild-type strains (Figure 9), revealed that YER1 is RPS14A(E54K). 
Unless we checked all of the gene mutations found in the coding region, we failed to identify 
the mutations in YER2 and YER3, suggesting that the YER2 and YER3 mutations were located 
on the noncoding region or repetitive sequences—for example, rDNA. RPS14A encodes a 
Figure 9. The work flow of the identification of RPS14A as a target of EudiC.
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component of the 40S ribosome, uS11, which participates not only in protein translation but 
also in 18S ribosomal RNA (rRNA) maturation (20S to 18S processing) in ribosome biogen-
esis with Fap7p [77]. To distinguish the effect of EudiC on uS11, we performed biochemical 
analysis using biotinylated EudiC and purified ribosome complexes. Because biotinylated 
EudiC failed to pull Fap7p down and no effect on 18S maturation processes was observed, it 
was confirmed that EudiC targets the matured 40S ribosome and inhibits protein translation 
but not rRNA maturation [50].
Collectively, our target ID studies of EudiC suggested the mode of action of EudiC cytotoxic-
ity and indicated that our sensitive strains would be quite useful for performing drug target 
IDs in a relatively short period.
3. Conclusions and perspective
In the field of chemical biology, several model organisms, including yeast, worms, flies, and 
mice, have been used. Yeast is one of the most-used model organisms due to its ease of han-
dling and its genetic availability, but its drug resistance is sometimes an obstacle to inves-
tigation. To overcome this problem, we constructed two multidrug-sensitive yeast strains, 
12geneΔ0HSR and 12geneΔ0HSR-iERG6. These strains not only show a broad spectrum of 
drug sensitivities against compounds for which resistance is shown by both ABC transport-
ers and ergosterol without influencing transformation, mating, or sporulation efficiency, but 
they are also useful for drug screening. Indeed, we performed a screening of antifungal com-
pounds and protein translation regulators which skip stop codons and found some promis-
ing candidates. Using 12geneΔ0HSR-iERG6, we succeeded in improving the hit rate of drug 
screening from microbial broth. The screening of microbial broth which inhibits the growth of 
12geneΔ0HSR-iERG6 but not of the quadruplex mutant identified novel compounds suggested 
that our multidrug-sensitive strain-based screening using previously tested chemical sources 
in yeast screening could identify new bioactive compounds. Furthermore, as our screening 
system for readthrough compounds, genetically modified multidrug-sensitive strains can be 
applied for several types of screening such as a yeast 2-hybrid system-based protein-protein 
interaction modulators screening. Recently, a yeast 3-hybrid system has been applied for 
drug-protein interaction analysis [78]. In this study, the pdr5 snq2 yor1 triple mutant was used 
to increase the sensitivity of the system [78]. Our multidrug-sensitive yeast strain was thus 
shown to be useful for this kind of analysis. Moreover, we expect that the 12geneΔ0HSR 
and 12geneΔ0HSR-iERG6 strains will also be useful tools for genome-wide chemical biology 
studies such as synthetic lethal/sick genetic interaction analyses [19, 20], genome-wide over-
expression screening [21], and haploinsufficiency-chemical sensitive assays [22]. In addition, 
the genetic approach using our strains identified the 40S ribosome component uS11 as a target 
molecule of the cytotoxicity caused by the antiviral compound EudiC. Because it has been 
reported that protein translation is one of the targets for antiviral agents [79–81], the effect on 
the 40S ribosome and the inhibition of translation by EudiC may cause both the cytotoxicity 
and the antiviral activity. In contrast, it has also been reported that the uS11 protein interacts 
with the eS1 and eS26 proteins, which form part of the mRNA exit tunnel [82], and that the 
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eS1 protein is one of the contact sites for hepatitis C virus internal ribosome entry sites (IRES) 
[83, 84]. These reports might suggest that EudiC decreases the interaction between ribosomes 
and some of the viral IRES, and efficiently inhibits the translation of viral proteins compared 
to that of host mRNA. Elucidating the detailed inhibitory mechanism of EudiC on protein 
translation and its effects on IRES-dependent translation might promote the development of 
EudiC as a novel antiviral medicine.
Recently, it has been reported that RNAseq combined with Crisper/Cas9-based genome-editing 
technologies is useful for target ID in mammalian cells [25]. Identification of the drug target 
using our multidrug-sensitive strains and confirmation of the identified mutation in mamma-
lian cells by Crisper/Cas9-based genome editing will reveal the mechanisms of drugs in more 
detail. Our multidrug-sensitive strains have the potential to facilitate chemical genetic studies 
and contribute to the development of medicines in the future.
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